BIB Ultra Nasdaq Biotechnology Proshares
- 57.050
- -0.440-0.77%
Puma Biotechnology Says Jury Verdict Was Entered In Favor Of Wyeth, And Against AstraZeneca; Jury Found '314 & '162 Patents To Be Infringed By AstraZeneca And Not Invalid, Awarded Plaintiffs $107.5M In Damages
Puma Biotechnology Says Jury Verdict Was Entered In Favor Of Wyeth, And Against AstraZeneca; Jury Found '314 & '162 Patents To Be Infringed By AstraZeneca And Not Invalid, Awarded Plaintiffs $107.5M I
Amgen Unusual Options Activity
Investors with a lot of money to spend have taken a bullish stance on Amgen (NASDAQ:AMGN).And retail traders should know.We noticed this today when the trades showed up on publicly available options h
Puma Biotech Surges Amid Wyeth Victory in Tagrisso Patent Case
Biontech Says European Patent Office's Decision To Maintain Moderna's Patent EP No. 3 590 949 B1 In Amended Form Does Not Change Co's Stance On Patent; Says "Believe That Neither Ep '949 Nor Any Of The Auxiliary Requests Filed By Moderna Meet The...
Biontech Says European Patent Office's Decision To Maintain Moderna's Patent EP No. 3 590 949 B1 In Amended Form Does Not Change Co's Stance On Patent; Says "Believe That Neither Ep '949 Nor Any Of Th
Pfizer "Disappointed" About 1st Instance Decision By Opposition Division Of European Patent Office To Maintain Moderna's European Patent Ep3590949 B1; Says Will Consider All Legal Options And May Appeal Decision By European Patent Office
Pfizer "Disappointed" About 1st Instance Decision By Opposition Division Of European Patent Office To Maintain Moderna's European Patent Ep3590949 B1; Says Will Consider All Legal Options And May Appe
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Moderna Vaccine Patent Upheld by European Patent Office: Report
Moderna Says European Patent Office Decided To Maintain Validity Of Co's EP949 Patent, One Of The Key Patents Currently Asserted Against Pfizer & BioNTech In Various European National Courts
Moderna Says European Patent Office Decided To Maintain Validity Of Co's EP949 Patent, One Of The Key Patents Currently Asserted Against Pfizer & BioNTech In Various European National Courts
'Moderna Wins Case In Patent Dispute With Pfizer And BioNTech Over Covid Jab; Decision Is A Boon For The MRNA-Vaccine Maker In Its Legal Fight To Recoup Pandemic Profits From Rivals' - Financial Times
Moderna has won a case at the European Patent Office in its dispute with Pfizer and BioNTech over its Covid-19 vaccine, in a boon for the mRNA-vaccine maker in its ongoing legal fight to recoup pandem
Check Out What Whales Are Doing With MRNA
Investors with a lot of money to spend have taken a bullish stance on Moderna (NASDAQ:MRNA).And retail traders should know.We noticed this today when the trades showed up on publicly available options
FDA Gives Accelerated Approval To Amgen's Drug For Small Cell Lung Cancer Patients
Thursday, the FDA approved Amgen Inc's (NASDAQ:AMGN) Imdelltra (tarlatamab-dlle) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on o
Regeneron Wins Temporary Restraining Order Preventing Eylea Generics
Reported Earlier, FDA Approves Amgen's IMDELLTRA (Tarlatamab-dlle) The First And Only T-Cell Engager Therapy For The Treatment Of Extensive-Stage Small Cell Lung Cancer
Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid TumorIMDELLTRA Demonstrated Impressive 40% Objective Response Rate, 9.7 Month Median Duration of Response and 14.3 Month Median Overall Su
Amgen's small cell lung cancer treatment approved by the FDA: can reduce tumors and prolong life
① On Thursday (May 17), the US FDA approved a method for treating widespread small-cell lung cancer by Amgen; ② The drug is generically named Tarlatamab and will be launched under the name Imdelltra; ③ Phase II trial results showed that after taking a specific dose of Tarlatamab, patients' cancer tumors shrunk by an average of 40%, increasing the average lifespan by one year.
Amgen Wins FDA Nod for New Lung Cancer Therapy
Watching Amgen; Hearing Co Wins U.S. Approval For Advanced Small Cell Lung Cancer
Watching Amgen; Hearing Co Wins U.S. Approval For Advanced Small Cell Lung Cancer
Biogen Also Drops Collaboration With Ionis on Angelman Syndrome Candidate
Truist Securities Maintains Buy on Biogen, Maintains $340 Price Target
Truist Securities analyst Robyn Karnauskas maintains Biogen (NASDAQ:BIIB) with a Buy and maintains $340 price target.
Biogen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/16/2024 48.11% Truist Securities $340 → $340 Maintains Buy 05/03/2024 48.98% HSBC $339 → $342 Maintains
Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another
Thursday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Biogen Inc (NASDAQ:BIIB) decided to terminate the development of BIIB105 (ION541), an investigational antisense oligonucleotide (ASO) for amyotrop